Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.71 |
| ▸ | EGFR | P00533 | 4/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376894 | 0.88 | ERBB2 (1.00) | ERBB2KCNH2EGFR | |
| SCHEMBL3375364 | 0.88 | ERBB2 (1.00) | ERBB2KCNH2EGFR | |
| SCHEMBL4197751 | 0.88 | ERBB2 (0.69) | ERBB2KCNH2EGFRERBB4 | |
| SCHEMBL4189683 | 0.86 | ERBB2 (0.78) | ERBB2KCNH2EGFRERBB4 | |
| SCHEMBL5637026 | 0.84 | ERBB2 (0.85) | ERBB2KCNH2EGFR | |
| SCHEMBL5572097 | 0.83 | ERBB2 (1.00) | ERBB2KCNH2EGFR | |
| SCHEMBL5635979 | 0.83 | ERBB2 (1.00) | ERBB2KCNH2EGFR | |
| SCHEMBL4189935 | 0.83 | ERBB2 (0.69) | ERBB2KCNH2EGFRERBB4 | |
| SCHEMBL4073005 | 0.83 | ERBB2 (0.61) | ERBB2KCNH2EGFRERBB4 | |
| SCHEMBL3377003 | 0.82 | ERBB2 (0.88) | ERBB2KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | claimed |
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | ERBB2 2/4885KCNH2 3976/4885EGFR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.